cdk1/cycb

(R)-Atuveciclib is an isomer of Atuveciclib. Atuveciclib (BAY 1143572) is a potent and highly selective PTEFb CDK9 inhibitor with an IC50 value of 13 nm for CDK9 CycT1 and a selectivity ratio of 100 for CDK2, with highly bioavailable and orally available advantages.

NVP-2 is an effective and selective ATP-competitive cyclin-dependent kinase 9 (CDK9) probe. NVP-2 induces cell apoptosis. NVP-2 inhibits CDK9 CycT activity (IC50: 0.514 nM). NVP-2 shows inhibitory effcts on CDK1 CycB, CDK2 CycA and CDK16 CycY kinases (IC5

Voruciclib is an orally active and selective CDK inhibitor (Ki: 0.626 nM-9.1 nM) that represses the expression of MCL-1 in multiple models of diffuse large B-cell lymphoma and effectively blocks CDK9, the transcriptional regulator of MCL-1.

Voruciclib hydrochloride is an orally active and selective CDK inhibitor with a Ki range of 0.626 nM to 9.1 nM.

PKC412(Midostaurin (PKC412); CGP41231; CGP41251) is a broad spectrum protein kinase inhibitor. Midostaurin inhibits protein kinase C alpha (PKCalpha), vascular endothelial growth factor receptor 2 (VEGFR2), c-kit, platelet-derived growth factor receptor (PDGFR) and FMS-like tyrosine kinase 3 (FLT3) tyrosine kinases, which may result in disruption of the cell cycle, inhibition of proliferation, apoptosis, and inhibition of angiogenesis in susceptible tumors.

CDK1-IN-7 is a potent inhibitor of CDK1 with an IC50 value of 161.2 nM for CDK1 CycB. CDK1-IN-7 induces apoptosis in a p53-dependent manner via the apoptosis-intrinsic pathway. CDK1-IN-7 selectively acts on tumour tissue and has potential anti-proliferative effects. CDK1-IN-7 is a potential CDK1-IN-7 is a potential targeted anti-tumour agent.

CDKi hydrochloride is a potent and selective ATP competitive inhibitor of cycB-CDK1, cycE-CDK2, and cycD1-CDK4.